UCSF Precision Cancer Medicine Building — San Francisco, California

UCSF Precision Cancer Medicine Building is a clinical research site located in San Francisco, California, United States 94158.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

UCSF Precision Cancer Medicine Building has participated in 1 clinical trials.

Therapeutic areas: Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia.

Sponsors: Prelude Therapeutics.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in San Francisco

Browse all research sites in California · View every site in San Francisco

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UCSF Precision Cancer Medicine Building?

UCSF Precision Cancer Medicine Building has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UCSF Precision Cancer Medicine Building conducted?

UCSF Precision Cancer Medicine Building has 1 clinical trials on record. Their work covers Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia.

Is UCSF Precision Cancer Medicine Building accredited by Crixeo Clinical Trials?

UCSF Precision Cancer Medicine Building has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UCSF Precision Cancer Medicine Building?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.